Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

NCT07248696 NA ACTIVE_NOT_RECRUITING

This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma

Details

Lead sponsor	Chongqing University Cancer Hospital
Phase	NA
Status	ACTIVE_NOT_RECRUITING
Enrolment	32
Start date	Sat Oct 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jun 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Nasopharyngeal Cancinoma (NPC)

Interventions

• response-adapted radiotherapy

Countries

China